文献速递结核与非结核分枝杆菌

耐药结核暴露家庭接触者预防治疗不良事件风险因素

Risk Factors for Adverse Events in Household Contacts Prescribed Preventive Treatment for Drug-resistant Tuberculosis Exposure.
PubMed 文献 · Clin Infect Dis · 2021-01-01

该研究在巴基斯坦卡拉奇纳入172名耐药结核患者家庭接触者,接受6个月氟喹诺酮类二药预防方案。21%发生不良事件,乙硫异烟胺组风险高于乙胺丁醇组(aHR 2.1,95%CI 1.2-3.6),总体耐受良好。

要点

  • 氟喹诺酮类二药预防方案总体耐受良好,无3/4级不良事件。
  • 含乙硫异烟胺方案不良事件风险高于含乙胺丁醇方案(aHR 2.1)。
  • 发生不良事件者与未发生者治疗完成率无显著差异(cOR 1.1)。

核心结论

  • 氟喹诺酮类耐药结核预防方案耐受良好。
  • 含乙硫异烟胺方案不良事件风险更高。

研究设计与样本

  • 在巴基斯坦卡拉奇开展的家庭接触者研究,172名接触者接受6个月氟喹诺酮类二药预防治疗。
  • 采用Kaplan-Meier曲线和Cox比例风险模型分析风险因素,并考虑复发。

主要发现

  • 172名接触者中36名(21%)发生64例不良事件,治疗总月数813个月。
  • 6个月治疗期间不良事件发生率为7.9/100人月;含氟喹诺酮+乙硫异烟胺为16/100人月,含氟喹诺酮+乙胺丁醇为4.4/100人月。
  • 不良事件中53例(83%)为1级,11例为2级,无3级或4级。
  • 多变量分析显示,调整年龄、性别和BMI后,乙硫异烟胺组不良事件风险高于乙胺丁醇组(aHR 2.1,95%CI 1.2-3.6)。

临床怎么用

  • 对耐药结核暴露家庭接触者选择预防方案时,需权衡乙硫异烟胺相关不良事件风险。
  • 氟喹诺酮类联合乙胺丁醇方案可能耐受性更优。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Completion of tuberculosis (TB) preventive treatment is important to optimize efficacy; treatment-related adverse events (AEs) sometimes result in discontinuation. This study describes the occurrence of AEs and their risk factors during a 6-month, 2-drug, fluoroquinolone-based preventive treatment for household contacts of patients with drug-resistant TB in Karachi, Pakistan. METHODS: The primary outcome was development of any clinical AE during preventive treatment. Adverse events were categorized using the AE grading tables of the National Institutes of Health. Time-to-event analysis with Kaplan-Meier curves and Cox proportional hazards models accounting for recurrence were used to analyze associated risk factors. RESULTS: Of the 172 household contacts on preventive treatment, 36 (21%) developed 64 AEs during 813 months of treatment. The incidence of AEs over 6 months of treatment was 7.9 per 100 person-months; 16 per 100 person-months with a fluoroquinolone and ethionamide, and 4.4 per 100 person-months with a fluoroquinolone and ethambutol. There were 53 (83%) grade 1 and 11 grade 2 AEs, with no grade 3 or 4 AEs. In multivariable analysis, the risk of AEs was higher in contacts prescribed ethionamide as compared to ethambutol adjusting for age, sex, and body mass index (adjusted hazard ratio, 2.1 [95% confidence interval {CI}, 1.2-3.6]). Overall, there was no notable difference in treatment completion among the contacts who experienced an AE and those who did not (crude odds ratio, 1.1 [95% CI, .52-2.5]). CONCLUSIONS: A fluoroquinolone-based preventive treatment regimen for drug-resistant TB exposure is well tolerated. Regimens with ethionamide are more likely to result in AEs.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Malik AA, Becerra MC, Lash TL, et al. Risk Factors for Adverse Events in Household Contacts Prescribed Preventive Treatment for Drug-resistant Tuberculosis Exposure. Clin Infect Dis. 2021. PMID: 32266942. doi:10.1093/cid/ciaa327

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。